188 related articles for article (PubMed ID: 24060477)
1. GPR119 agonists: a promising approach for T2DM treatment? A SWOT analysis of GPR119.
Kang SU
Drug Discov Today; 2013 Dec; 18(23-24):1309-15. PubMed ID: 24060477
[TBL] [Abstract][Full Text] [Related]
2. The therapeutic potential of GPR119 agonists for type 2 diabetes.
Ohishi T; Yoshida S
Expert Opin Investig Drugs; 2012 Mar; 21(3):321-8. PubMed ID: 22292451
[TBL] [Abstract][Full Text] [Related]
3. Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus.
Ha TY; Kim YS; Kim CH; Choi HS; Yang J; Park SH; Kim DH; Rhee JK
Arch Pharm Res; 2014 May; 37(5):671-8. PubMed ID: 23897163
[TBL] [Abstract][Full Text] [Related]
4. GPR119 agonists for the treatment of type 2 diabetes.
Jones RM; Leonard JN; Buzard DJ; Lehmann J
Expert Opin Ther Pat; 2009 Oct; 19(10):1339-59. PubMed ID: 19780700
[TBL] [Abstract][Full Text] [Related]
5. GPR119 agonists: a promising new approach for the treatment of type 2 diabetes and related metabolic disorders.
Shah U
Curr Opin Drug Discov Devel; 2009 Jul; 12(4):519-32. PubMed ID: 19562648
[TBL] [Abstract][Full Text] [Related]
6. Deal watch: Metabolex and Sanofi-Aventis partner on GPCR agonists for type 2 diabetes.
Nat Rev Drug Discov; 2010 Sep; 9(9):670. PubMed ID: 20811370
[No Abstract] [Full Text] [Related]
7. GPR119 agonists for the potential treatment of type 2 diabetes and related metabolic disorders.
Shah U; Kowalski TJ
Vitam Horm; 2010; 84():415-48. PubMed ID: 21094910
[TBL] [Abstract][Full Text] [Related]
8. [GPR119 Receptor Agonists: Characteristics, Physiological Role, Prospects of Use in the Treatment of Diabetes Mellitus Type 2 and Metabolic Syndrome].
Tyurenkov IN; Kurkin DV; Bakulin DA; Lomkina EM; Volotova EV
Usp Fiziol Nauk; 2015; 46(4):28-37. PubMed ID: 27183782
[TBL] [Abstract][Full Text] [Related]
9. GPR119 agonists 2009-2011.
Buzard DJ; Lehmann J; Han S; Jones RM
Pharm Pat Anal; 2012 Jul; 1(3):285-99. PubMed ID: 24236842
[TBL] [Abstract][Full Text] [Related]
10. GPR119 agonists for the treatment of type 2 diabetes: an updated patent review (2014-present).
Li H; Fang Y; Guo S; Yang Z
Expert Opin Ther Pat; 2021 Sep; 31(9):795-808. PubMed ID: 33896337
[No Abstract] [Full Text] [Related]
11. Discovery of structurally novel, potent and orally efficacious GPR119 agonists.
Alper P; Azimioara M; Cow C; Mutnick D; Nikulin V; Michellys PY; Wang Z; Reding E; Paliotti M; Li J; Bao D; Zoll J; Kim Y; Zimmerman M; Groessel T; Tuntland T; Joseph SB; McNamara P; Seidel HM; Epple R
Bioorg Med Chem Lett; 2014 May; 24(10):2383-7. PubMed ID: 24751443
[TBL] [Abstract][Full Text] [Related]
12. [The role of pharmacology to produce firuglipel (DS-8500a), an orally available GPR119 agonist for type 2 diabetes mellitus].
Matsumoto K; Yoshitomi T; Shimada T
Nihon Yakurigaku Zasshi; 2018; 152(3):119-124. PubMed ID: 30185729
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel trans-1,4-dioxycyclohexane GPR119 agonist series.
Han S; Narayanan S; Kim SH; Calderon I; Zhu X; Kawasaki A; Yue D; Lehmann J; Wong A; Buzard DJ; Semple G; Carroll C; Chu ZL; Al-Sharmma H; Shu HH; Tung SF; Unett DJ; Behan DP; Yoon WH; Morgan M; Usmani KA; Chen C; Sadeque A; Leonard JN; Jones RM
Bioorg Med Chem Lett; 2015 Aug; 25(15):3034-8. PubMed ID: 26048791
[TBL] [Abstract][Full Text] [Related]
14. GPR119 as a fat sensor.
Hansen HS; Rosenkilde MM; Holst JJ; Schwartz TW
Trends Pharmacol Sci; 2012 Jul; 33(7):374-81. PubMed ID: 22560300
[TBL] [Abstract][Full Text] [Related]
15. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
Zhou Y; Wang Y; Zhang L; Tang C; Feng B
Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
[TBL] [Abstract][Full Text] [Related]
16. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
[TBL] [Abstract][Full Text] [Related]
17. GPR119 agonists: Novel therapeutic agents for type 2 diabetes mellitus.
Manaithiya A; Alam O; Sharma V; Javed Naim M; Mittal S; Khan IA
Bioorg Chem; 2021 Aug; 113():104998. PubMed ID: 34048996
[TBL] [Abstract][Full Text] [Related]
18. GPR119 agonists for type 2 diabetes: past failures and future hopes for preclinical and early phase candidates.
Hryciw DH; Patten RK; Rodgers RJ; Proietto J; Hutchinson DS; McAinch AJ
Expert Opin Investig Drugs; 2024 Mar; 33(3):183-190. PubMed ID: 38372052
[TBL] [Abstract][Full Text] [Related]
19. Is GPR119 agonism an appropriate treatment modality for the safe amelioration of metabolic diseases?
Cornall LM; Mathai ML; Hryciw DH; McAinch AJ
Expert Opin Investig Drugs; 2013 Apr; 22(4):487-98. PubMed ID: 23442069
[TBL] [Abstract][Full Text] [Related]
20. The significance of GPR119 agonists as a future treatment for type 2 diabetes.
Dhayal S; Morgan NG
Drug News Perspect; 2010 Sep; 23(7):418-24. PubMed ID: 20862393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]